Literature DB >> 4427225

Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite.

P H Hinderling, J Bres, E R Garrett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4427225     DOI： 10.1002/jps.2600631103

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  32 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

3.  Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.

Authors:  H Echizen; M Nakura; T Saotome; S Minoura; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

Review 4.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

5.  Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.

Authors:  S M Bryson; B Whiting; J R Lawrence
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

6.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.

Authors:  M L Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

7.  Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.

Authors:  K M Giacomini; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

8.  The influence of various factors in the in vitro distribution of haloperidol in human blood.

Authors:  I E Hughes; L B Jellett; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

9.  Kinetics of disopyramide in decreased hepatic function.

Authors:  J Bonde; N A Graudal; L E Pedersen; S Balsløv; H R Angelo; T L Svendsen; J P Kampmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.